<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909907</url>
  </required_header>
  <id_info>
    <org_study_id>15-1519</org_study_id>
    <nct_id>NCT02909907</nct_id>
  </id_info>
  <brief_title>Comparison of Botulinum Toxin Injections in Forearm FLexor Plus EXtensor Muscles vs. Flexor Muscles Alone for Treatment of Essential Hand Tremor(FLEX-D ET)</brief_title>
  <acronym>FLEX-D ET</acronym>
  <official_title>Comparison of Botulinum Toxin Injections in Forearm FLexor Plus EXtensor Muscles Versus Flexor Muscles Alone for the Treatment of Essential Hand Tremor (FLEX-D ET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of botulinum toxin (BoNT) injections in forearm flexors plus extensor
      muscles versus flexors alone for the treatment of essential hand tremor (ET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a pilot, single center, double blind, randomized, parallel, placebo
      controlled trial comparing 2 (BoNT) injection patterns for treatment of moderate to severe
      essential tremor. The investigators will recruit 20 patients with (ET).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the 6 Week Post Injection Patient Global Impression of Improvement Scale (PGIS) Between Flexors Along and Flexors Plus Extensors Groups.</measure>
    <time_frame>6 weeks</time_frame>
    <description>6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by the patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Tremor Rating Scale Score (TSR)Change From Baseline to Week 6 Between Flexors Alone and Flexors Plus Extensors Groups.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none/normal and 4 = very severe/high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the 6 Week Post Injection Clinician Global Impression of Improvement Scale (CGIS) Between Flexors Along and Flexors Plus Extensors Groups.</measure>
    <time_frame>6 weeks</time_frame>
    <description>6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of the Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 6 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index.Positive index change values indicate that the score increased and negative values indicate that the score decreased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the Post Injection Grip Strength Change Between Flexor Only Group and Flexor and Extensors Group at 6 Weeks.</measure>
    <time_frame>6 weeks</time_frame>
    <description>the median of the differences in grip strength between baseline and week 6, A negative value indicates a decrease in grip strength in Kg at week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 Weeks Post Injection Tremor Rating Scale for Flexors Group and Flexors Plus Extensors Group.</measure>
    <time_frame>12 weeks</time_frame>
    <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none or normal and 4 = very severe or high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 Week Post Injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>12 week post injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)
Assessment of improvement graded by the clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 Week Post Injection Patient Global Impression Scale-Improvement Subscale (PGIS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient Global Impression Scale-Improvement Subscale (PGIS)
Assessment of improvement graded by patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 12 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group.</measure>
    <time_frame>Baseline and 12 weeks.</time_frame>
    <description>QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index. Positive index change values indicate that the score increased and negative values indicate that the score decreased.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>150 units of abobotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 units of abobotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin</intervention_name>
    <description>Botulinum injections into dominant upper extremity using protocol outlined above.</description>
    <arm_group_label>150 units of abobotulinumtoxinA</arm_group_label>
    <arm_group_label>75 units of abobotulinumtoxinA</arm_group_label>
    <other_name>BoNT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
    <arm_group_label>150 units of abobotulinumtoxinA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 and over, male or female patient with (ET) involving at least their dominant
             hand, as diagnosed by a movement disorders neurologist.

          2. Having bothersome hand tremor in dominant hand with a hand TRS ≥2

          3. On stable medications during last 30 days prior to enrollment.

        Exclusion Criteria:

          1. Presence of secondary causes of tremor, such as dystonia and parkinsonism

          2. Any contraindication to botulinum toxin injections (e.g. motor neuron disease,
             neuromuscular junction disease, etc.)

          3. History of surgical treatment for (ET).

          4. Dementia as defined by DSM-V criteria

          5. Patients with suboptimally treated depression and significant depressive symptoms as
             defined by a PHQ-9 score of ≥15 (PHQ-9 scores 1-4 Minimal depression; 5-9 Mild
             depression; 10-14 Moderate depression; 15-19 Moderately severe depression; 20-27
             Severe depression). Antidepressant medications, prescribed for depression or anxiety,
             will be allowed if the patient has been on a stable dose for at least 30 days.

          6. Patients with suboptimally treated anxiety and significant anxiety symptoms as defined
             by a GAD-7 score of ≥15 (GAD-7 scores 0-4: minimal anxiety; 5-9: mild anxiety; 10-14:
             moderate anxiety; 15-21: severe anxiety). Anti-anxiety medications, prescribed for
             anxiety, will be allowed if the patient has been on a stable dose for at least 30
             days.

          7. Significant renal, hepatic, cardiac and thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <results_first_submitted>February 5, 2019</results_first_submitted>
  <results_first_submitted_qc>April 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02909907/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 12-week, pilot, randomized (1:1 ratio), double-blind, placebo-controlled study of 21 patients with ET evaluated by a movement disorders specialist at the Cleveland Clinic.</recruitment_details>
      <pre_assignment_details>Twenty-one patients were enrolled to participate, but one patient was removed from the sample due to being an extreme outlier on most outcomes of interest, and another patient dropped out after the baseline visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Flexors Alone</title>
          <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
        </group>
        <group group_id="P2">
          <title>Flexors Plus Extensors</title>
          <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flexors Alone</title>
          <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
        </group>
        <group group_id="B2">
          <title>Flexors Plus Extensors</title>
          <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" spread="12.0"/>
                    <measurement group_id="B2" value="64.9" spread="9.1"/>
                    <measurement group_id="B3" value="69.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Right-handed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TRS mean</title>
          <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none or normal and 4 = very severe or high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" spread="4.6"/>
                    <measurement group_id="B2" value="11.3" spread="4.1"/>
                    <measurement group_id="B3" value="12.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Health status self-report, med(IQR)</title>
          <description>QUEST ( Quality of life in Essential tremor Questionnaire )
Heath Status:
In general, how would you rate your overall health? (0=very poor health, 100=excellent/perfect health)
Circle: 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.5" lower_limit="75" upper_limit="90"/>
                    <measurement group_id="B2" value="82.5" lower_limit="75" upper_limit="90"/>
                    <measurement group_id="B3" value="82.5" lower_limit="75" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Quality of Life self-report, mean(SD)</title>
          <description>Quality of Life in Essential Tremor Questionnaire (QUEST)
Overall Quality of Life:
Overall, how would you rate your quality of life? (0=very poor health, 100=excellent/perfect health):
Circle: 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84" spread="9.7"/>
                    <measurement group_id="B2" value="82.8" spread="6.7"/>
                    <measurement group_id="B3" value="83.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Communication, med (IQR)</title>
          <description>Quality of Life in Essential Tremor Questionnaire (QUEST): Dimension Communication: total questions 3 Possible answers: Each answer correspond to a numeric value : N=0 R=1 S=2 F=3 A=4 NA=blank N = Never/Not applicable R = Rarely S = Sometimes F = Frequently A = Always/Yes Scoring Algorithm: Total applicable points for each dimension/total possible points ( # of applicable questionsx 4 ) for each dimension X100 = dimension score.
Maximal Score 100=worse quality of life due to tremor. Minimal score 0= Best quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Work, med (IQR)</title>
          <description>Quality of Life in Essential Tremor Questionnaire (QUEST): Dimension Work: total questions 6 Possible answers: Each answer correspond to a numeric value : N=0 R=1 S=2 F=3 A=4 NA=blank N = Never/Not applicable R = Rarely S = Sometimes F = Frequently A = Always/Yes Scoring Algorithm: Total applicable points for each dimension/total possible points ( # of applicable questionsx 4 ) for each dimension X100 = dimension score.
Maximal Score 100=worse quality of life due to tremor. Minimal score 0= Best quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="8.3"/>
                    <measurement group_id="B2" value="8.3" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Hobbies, med (IQR)</title>
          <description>Quality of Life in Essential Tremor Questionnaire (QUEST): Dimension Hobbies: total questions 3 Possible answers: Each answer correspond to a numeric value : N=0 R=1 S=2 F=3 A=4 NA=blank N = Never/Not applicable R = Rarely S = Sometimes F = Frequently A = Always/Yes Scoring Algorithm: Total applicable points for each dimension/total possible points ( # of applicable questionsx 4 ) for each dimension X100 = dimension score.
Maximal Score 100=worse quality of life due to tremor. Minimal score 0= Best quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="8.3"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="50"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Physical, med (IQR)</title>
          <description>Quality of Life in Essential Tremor Questionnaire (QUEST): Dimension Physical: total questions 9 Possible answers: Each answer correspond to a numeric value : N=0 R=1 S=2 F=3 A=4 NA=blank N = Never/Not applicable R = Rarely S = Sometimes F = Frequently A = Always/Yes Scoring Algorithm: Total applicable points for each dimension/total possible points ( # of applicable questionsx 4 ) for each dimension X100 = dimension score.
Maximal Score 100=worse quality of life due to tremor. Minimal score 0= Best quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" lower_limit="33.3" upper_limit="72.2"/>
                    <measurement group_id="B2" value="61.1" lower_limit="58.3" upper_limit="61.1"/>
                    <measurement group_id="B3" value="61.1" lower_limit="33.3" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Psychosocial, med (IQR)</title>
          <description>Quality of Life in Essential Tremor Questionnaire (QUEST): Dimension Communication: total questions 9 Possible answers: Each answer correspond to a numeric value : N=0 R=1 S=2 F=3 A=4 NA=blank N = Never/Not applicable R = Rarely S = Sometimes F = Frequently A = Always/Yes Scoring Algorithm: Total applicable points for each dimension/total possible points ( # of applicable questionsx 4 ) for each dimension X100 = dimension score.
Maximal Score 100=worse quality of life due to tremor. Minimal score 0= Best quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="B2" value="25" lower_limit="11" upper_limit="41.7"/>
                    <measurement group_id="B3" value="11.1" lower_limit="8.3" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QUEST Summary Index, med (IQR)</title>
          <description>Quality of Life in Essential Tremor Questionnaire: Total summary index
30-item, ET-specific quality of life scale
Items contribute to 5 dimensions: Physical/ADL, Psychosocial, Communication, Hobbies/Leisure, and Work/Finances. The score on each scale is a percentage of the total score possible, a higher score indicates greater dissatisfaction with that domain.
The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" lower_limit="10.6" upper_limit="20"/>
                    <measurement group_id="B2" value="26.4" lower_limit="17.8" upper_limit="29.4"/>
                    <measurement group_id="B3" value="17.8" lower_limit="11.1" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PHQ-9, med (IQR)</title>
          <description>Patient Health Questionnaire - 9 PHQ-9
9 question items scored from : 0=not at all , 1= Several Days, 2=More than half the days, 3=nearly every day .
Total score is the sum of all items.
Interpretation of Total Score Total Score Depression Severity 0-4 Minimal depression 5-9 Mild depression 10-14 Moderate depression 15-19 Moderately severe depression 20-27 Severe depression
Minimum score: 0 : no depression. Maximal Score 27 : severe depression.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="B2" value="4" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B3" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GAD-7, med (IQR)</title>
          <description>Generalized Anxiety Disorder 7 item ( GAD-7)
Total of 7 questions scored from 0=not at all , 1= several days, 2= More than half the days, 3= Nearly every day.
Total score = total sum of all items. Maximal score=21, minimal Score =0
Interpretation of the score:
&gt; or = 10 probable diagnosis of Generalized anxiety disorder, Confirm by further evaluation.
0–4: minimal anxiety 5–9: mild anxiety 10–14: moderate anxiety 15–21: severe anxiety</description>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="B2" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset, med (IQR)</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" lower_limit="25" upper_limit="73"/>
                    <measurement group_id="B2" value="58" lower_limit="40" upper_limit="64"/>
                    <measurement group_id="B3" value="58" lower_limit="30" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease duration, med (IQR)</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="2" upper_limit="42"/>
                    <measurement group_id="B2" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="B3" value="5" lower_limit="2" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Main Grip Strength</title>
          <units>Kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" lower_limit="22.7" upper_limit="36.7"/>
                    <measurement group_id="B2" value="28" lower_limit="26.7" upper_limit="33.3"/>
                    <measurement group_id="B3" value="29.7" lower_limit="23.7" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in the 6 Week Post Injection Patient Global Impression of Improvement Scale (PGIS) Between Flexors Along and Flexors Plus Extensors Groups.</title>
        <description>6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by the patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the 6 Week Post Injection Patient Global Impression of Improvement Scale (PGIS) Between Flexors Along and Flexors Plus Extensors Groups.</title>
          <description>6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by the patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.6" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Tremor Rating Scale Score (TSR)Change From Baseline to Week 6 Between Flexors Alone and Flexors Plus Extensors Groups.</title>
        <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none/normal and 4 = very severe/high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Tremor Rating Scale Score (TSR)Change From Baseline to Week 6 Between Flexors Alone and Flexors Plus Extensors Groups.</title>
          <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none/normal and 4 = very severe/high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-6" upper_limit="-4"/>
                    <measurement group_id="O2" value="-5" lower_limit="-6" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the 6 Week Post Injection Clinician Global Impression of Improvement Scale (CGIS) Between Flexors Along and Flexors Plus Extensors Groups.</title>
        <description>6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the 6 Week Post Injection Clinician Global Impression of Improvement Scale (CGIS) Between Flexors Along and Flexors Plus Extensors Groups.</title>
          <description>6 weeks post injection Clinician Global Impression if improvement Scale (CGIS)
Assessment of improvement graded by clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of the Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 6 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group.</title>
        <description>QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index.Positive index change values indicate that the score increased and negative values indicate that the score decreased.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of the Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 6 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group.</title>
          <description>QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index.Positive index change values indicate that the score increased and negative values indicate that the score decreased.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-1.7" upper_limit="5.6"/>
                    <measurement group_id="O2" value="-5.3" lower_limit="-6.11" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in the Post Injection Grip Strength Change Between Flexor Only Group and Flexor and Extensors Group at 6 Weeks.</title>
        <description>the median of the differences in grip strength between baseline and week 6, A negative value indicates a decrease in grip strength in Kg at week 6.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Post Injection Grip Strength Change Between Flexor Only Group and Flexor and Extensors Group at 6 Weeks.</title>
          <description>the median of the differences in grip strength between baseline and week 6, A negative value indicates a decrease in grip strength in Kg at week 6.</description>
          <units>Kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" lower_limit="-15.3" upper_limit="-5.3"/>
                    <measurement group_id="O2" value="-11" lower_limit="-13.3" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 Weeks Post Injection Tremor Rating Scale for Flexors Group and Flexors Plus Extensors Group.</title>
        <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none or normal and 4 = very severe or high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>12 Weeks Post Injection Tremor Rating Scale for Flexors Group and Flexors Plus Extensors Group.</title>
          <description>TRS: Tremor Rating Scale : scale composed of 6 items rated from 0-4. 0=none or normal and 4 = very severe or high level of disability. Total score is the sum of all items. Max score 24 ( maximal severity of tremor) Minimal score 0= no tremor/normal.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 Week Post Injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)</title>
        <description>12 week post injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)
Assessment of improvement graded by the clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>12 Week Post Injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)</title>
          <description>12 week post injection in Clinician Global Impression Scale-Improvement Subscale (CGIS)
Assessment of improvement graded by the clinician on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 Week Post Injection Patient Global Impression Scale-Improvement Subscale (PGIS)</title>
        <description>Patient Global Impression Scale-Improvement Subscale (PGIS)
Assessment of improvement graded by patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>12 Week Post Injection Patient Global Impression Scale-Improvement Subscale (PGIS)</title>
          <description>Patient Global Impression Scale-Improvement Subscale (PGIS)
Assessment of improvement graded by patient on a -4 to +4 scale
-4 = severe worsening
0 = no change
+4 = complete abolishment of symptoms
Higher scores represent better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 12 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group.</title>
        <description>QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index. Positive index change values indicate that the score increased and negative values indicate that the score decreased.</description>
        <time_frame>Baseline and 12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexors Alone</title>
            <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
          </group>
          <group group_id="O2">
            <title>Flexors Plus Extensors</title>
            <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Quality of Life in Essential Tremor Questionnaire (QUEST) Summary Index Change at Week 12 Compared to Baseline Between Wrist Flexors Versus Wrist Flexors Plus Extensors Group.</title>
          <description>QUEST( Quality of Life in Essential Tremor Questionnaire ) is a 30-item, ET-specific quality of life scale . Items contribute to five dimensions. Physical/ADL (9 items ), Psychosocial (9 items), Communication (3 items), Hobbies/Leisure (3 items), and Work/Finances (6 items). The score on each scale is expressed as a percentage of the total score possible, with a higher score indicating greater dissatisfaction with that domain of QOL. A total or summary index corresponds to the mean of the five domain scores. The total summary index corresponds to the mean of the five domain scores. Maximal score 100: worse quality of life. Minimal Score 0: best quality of life. This outcome represents the median of the differences between baseline and week 6 in QUEST summary index. Positive index change values indicate that the score increased and negative values indicate that the score decreased.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" lower_limit="-3.9" upper_limit="-0.56"/>
                    <measurement group_id="O2" value="0" lower_limit="-6.11" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flexors Alone</title>
          <description>75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.</description>
        </group>
        <group group_id="E2">
          <title>Flexors Plus Extensors</title>
          <description>150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
Botulinum toxin: Botulinum injections into dominant upper extremity using protocol outlined above.
Placebo: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Finger Weakness</sub_title>
                <description>Weakness of fingers</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hubert H Fernandez</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>2164451108</phone>
      <email>FERNANH@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

